TY  - JOUR
T1  - Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer
A1  - Havva Cinkir
A1  - Tulay Kus
A1  - Gokmen Aktas
A1  - Umut Elboga
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2021
VL  - 10
IS  - 6
DO  - 10.4103/ccij.ccij_185_20
SP  - 294
EP  - 299
N2  - 
Background: Adenocancer pathologic subtype, smoking history, and women gender have been known to predict the parameters such as the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC); however, we need new predictive markers as well as driver mutations for better treatment options. The aim of this study is to investigate the predictive role of sarcopenia in lung adenocancer patients treated with erlotinib. Materials and Methods: This study was designed as retrospectively. Skeletal muscle index (SMI) was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3, cm2)/(height × height)(m2). Sarcopenia was defined by median cutoff values of SMI of women (
UR  - https://ccij-online.org/article/sarcopenia-is-a-predictive-marker-for-response-to-erlotinib-in-patients-with-lung-adenocancer-933
ER  -